Michael Thurn

Company: Neurizon

Job title: Chief Executive Officer

Seminars:

Preclinical & Early Clinical Development of NUZ-001: A Novel mTOR Inhibitor Demonstrating Potential as a Therapeutic Agent for Amyotrophic Lateral Sclerosis 2:30 pm

• ALS and related TDP-43 proteinopathies are driven by the mislocalization and aggregation of TDP-43, leading to neurodegeneration; the concurrent loss of Stathmin-2 (STMN2), a key regulator of axonal repair, further accelerates disease progression and highlights the need for therapies targeting both TDP43 pathology and STMN2 restoration • NUZ-001, a novel small-molecule mTOR inhibitor, is…Read more

day: Conference Day Two PM